Letters: Correction about patent expiry for anti-malarial

In a recent update (GP, 15 May) it was stated that the patent for Malarone (combination atovaquone plus proguanil) expired in April 2009.

The patent for atovaquone monotherapy expired in April 2009 but that for Malarone does not expire until November 2013.

We feel that it is important to differentiate Malarone from atovaquone, so that the anti-malarial advice provided by your readers to travellers is as up-to-date and accurate as possible.

Pim Kon, GSK medical director, Uxbridge, south London

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us: